TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03574571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2
Description: Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2
Description: Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
Study: NCT02859675

Intervention type: OTHER
Intervention: Questionnaires
Description: Stunkard, PrefQuest
Study: NCT01054040

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Portion plate given to cardiac rehabilitation patients
Description: Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
Study: NCT04712903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
Study: NCT02859675

Intervention type: OTHER
Intervention: Questionnaires
Description: Stunkard, PrefQuest

Intervention type: OTHER
Intervention: Questionnaires
Description: Stunkard, PrefQuest
Study: NCT03406104

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS010
Description: Lenadogene nolparvovec Intravitreal ocular unilateral Injection
Study: NCT03858855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy and Essential Oils
Description: Use bergamot essential oil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy and Essential Oils
Description: Use chamomile essential oil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy and Essential Oils
Description: Use ginger essential oil
Study: NCT03406104

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intravitreal Injection
Description: Lenadogene nolparvovec Intravitreal ocular unilateral Injection
Study: NCT01204164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 citrate
Description: TG02 citrate capsules given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 citrate
Description: TG02 citrate capsules given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 citrate
Description: TG02 citrate capsules given orally.
Study: NCT03858855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy and Essential Oils
Description: Use almond essential oil
Study: NCT01204164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 citrate
Description: TG02 citrate capsules given orally.
Study: NCT03858855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject Diary
Description: Complete journal
Study: NCT01204164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib per PI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib per PI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (Oral or IV)
Study: NCT01772706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low level laser therapy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo (laser low level energy nonfunctional)
Study: NCT01659463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICON
Description: LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: instruction oral hygiene
Description: Instructions diet and hygiene oral and topical fluoride
Study: NCT01267812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT03900858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid；Rifapentine
Description: 1 months (12 doses) of three-weekly rifapentine at a dose of 450mg plus isoniazid at a dose of 400mg given under direct observation
Study: NCT01267812

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Study: NCT02399280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lunch as main meal(LM)+ Diet
Description: Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dinner as main meal(DM)+ Diet
Description: Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
Study: NCT04098237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Pancrelipase delayed-release capsules
Study: NCT03969394

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Medical imaging
Description: Medical Imaging consisting of 1 MRI and 1 echocardiography at baseline
Study: NCT02403635

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam

Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151
Study: NCT04489212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Review of medical chart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00708006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGS1029
Description: Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
Study: NCT02747901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KINESIOTAPING
Description: Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COLD THERAPY
Description: Cold therapy group received cold packs immediately after operation and following postoperative days
Study: NCT02496533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand Massage
Description: The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
Study: NCT03249298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterofundin (Bolus of crystalloids)
Description: Bolus of 250 ml crystaloids infused regarding the measures

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (Bolus of colloids)
Description: Bolus of 250 ml colloids infused regarding the measures
Study: NCT00760461

Intervention type: DRUG
Group type: OTHER
Intervention: Domperidone
Description: 10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
Study: NCT03740542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Surgical removal of part of esophagus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Surgical removal of part of esophagus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pyloroplasty
Description: pyloric drainage procedure
Study: NCT01690546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: very low dose naltrexone
Description: On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release naltrexone
Description: On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
Study: NCT03362931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XEN45
Description: XEN45 unilaterally implanted in the study eye
Study: NCT02238431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucrin depot
Description: scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCP
Description: to schedule the start of the artificial cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural
Description: to use the normal menstrual period to schedule treatment start
Study: NCT03824327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Oxygen Level Dependent Imaging
Description: Undergo BOLD fMRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papaverine Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT05075304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: IV infusions of Injection diluted in sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: IV infusions of Injection diluted in sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: IV infusions of Injection diluted in sodium chloride
Study: NCT03864250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: The initial dose of prednisone is 0.5 mg/kg/d orally (maximum dose 40 mg/d), and after 8-12 weeks, the dose was gradually reduced until discontinuation. TAC treatment is given at the same time (the treatment plan is the same as the experimental group).
Study: NCT03886012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otoband
Description: The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Otoband sham
Description: The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.
Study: NCT03328169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy
Description: Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
Study: NCT00246025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Dabigatran etexilate 110 mg capsule, once a day, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Dabigatran etexilate 150 mg capsule, once a day, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Dabigatran etexilate 220 mg capsule, once a day, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo capsule, once a day, oral administration
Study: NCT01593995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF) ointment
Description: EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect
Study: NCT01858805

Intervention type: PROCEDURE
Intervention: esophagectomy
Study: NCT04960878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Synbiotics sachet mainly contained Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, and fructooligosaccharides.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT03109808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-health strategy
Description: * First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~* Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Oral Hygiene Education
Description: traditional oral hygiene education
Study: NCT03360890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.
Study: NCT00481715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Weight Loss Program
Description: Participants will take part in a Web-based weight loss program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Weight Loss Program
Description: Participants will take part in a Web-based weight loss program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Incentive Weight Loss Program
Description: Participants will take part in a cash incentive weight loss program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Incentive Weight Loss Program
Description: Participants will take part in a cash incentive weight loss program.
Study: NCT02968927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 0.5 MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin 6 MG
Study: NCT03142555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk plus intensive social media intervention
Description: Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
Study: NCT02968927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-11050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2HRbZE/4HRb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2HRbZE/4HRb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2HRbZE/4HRb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2HRbZE/4HRb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2HRbZE/4HRb
Study: NCT03142555

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health talk plus less intensive social media intervention
Description: Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
Study: NCT00909545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isradipine CR 5mg
Description: 5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isradipine CR 10mg
Description: 10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isradipine CR 20mg
Description: 20mg dose: 4 Dynacirc CR 5mg tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 Placebo to Match (PTM) tablets once daily
Study: NCT03946124

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.
Study: NCT01310400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agrippal
Description: Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28
Study: NCT00529126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: SKY0402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: SKY0402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: SKY0402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl